

NEWS RELEASE

December 13, 2018

Methapharm announces US launch of ARIDOL® (mannitol bronchial challenge test)

Methapharm is pleased to announce the US launch of ARIDOL® (mannitol bronchial challenge test). Methapharm licensed commercial rights to ARIDOL for the US and Canada from Pharmaxis Ltd. of Australia. Pharmaxis received US FDA approval for their manufacturing site earlier this year. Additionally, a marketing authorization application for ARIDOL has been submitted to Health Canada and Methapharm anticipates an approval in late 2019.

About Methapharm

Methapharm is a specialty pharmaceutical company that focuses on the development, acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own proprietary products as well as partners with global companies in order to deliver a line of products in the USA and Canada. For more information about Methapharm, please visit www.methapharm.com

About Pharmaxis

Pharmaxis (ACN 082 811 630) is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office, manufacturing and research facilities are located in Sydney, Australia. For more information about Pharmaxis, please visit www.pharmaxis.com.au

###

For more information about Methapharm or business development inquiries, please contact:

Chris Calenti
Executive Vice President
Business Development & Licensing
Tel: (+1) 519.751.3602 x7222